Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teva Pharmaceutical (TEVA) and DENTSPLY SIRONA (XRAY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teva Pharmaceutical (TEVA – Research Report) and DENTSPLY SIRONA (XRAY – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Teva Pharmaceutical (TEVA)
In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Teva Pharmaceutical, with a price target of $36.00. The company’s shares closed last Thursday at $32.35.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
Currently, the analyst consensus on Teva Pharmaceutical is a Strong Buy with an average price target of $36.86, a 14.3% upside from current levels. In a report issued on January 11, J.P. Morgan also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
DENTSPLY SIRONA (XRAY)
In a report released today, Allen Lutz from Bank of America Securities maintained a Hold rating on DENTSPLY SIRONA. The company’s shares closed last Thursday at $12.58.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
DENTSPLY SIRONA has an analyst consensus of Hold, with a price target consensus of $13.00, implying a 5.9% upside from current levels. In a report issued on January 14, TipRanks – PerPlexity also upgraded the stock to Hold with a $13.00 price target.
